BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment
- British Thoracic Society Standards of Care Committee*
- Correspondence to:
Professor L P Ormerod
Professor of Respiratory Medicine, Blackburn Royal Infirmary, Blackburn, Lancashire BB2 3LR, UK;
- Received 15 May 2005
- Accepted 26 June 2005
- Published Online First 29 July 2005
Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor α (anti-TNF-α) treatment. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.
↵* Members of the BTS Standards of Care Subcommittee: L P Ormerod (Chair)1, H J Milburn2, S Gillespie3, J Ledingham4, D Rampton5.
1Consultant Chest Physician, Blackburn Royal Infirmary, Blackburn, Lancs BB2 3LR, UK
2Consultant Chest Physician, Guy’s and St Thomas’ Hospitals, London SE1 9RT
3Consultant Microbiologist, Department of Medical Microbiology, Royal Free and University College Medical School, London NW3 2PF
4Consultant Rheumatologist, Queen Alexandra Hospital, Portsmouth PO6 3LY (representing the British Society of Rheumatology)
5Consultant Gastroenterologist, Barts and the London NHS Trust, London E1 1BB (representing the British Society of Gastroenterology)
Published Online First 29 July 2005